Eye movements may reveal Parkinson's progression
NCT ID NCT04731246
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 30 people with mild-to-moderate Parkinson's disease for up to 7 years. Researchers use a video eye-tracking device to measure eye movements and compare them with standard neurological and cognitive tests. The goal is to see if eye-tracking can serve as a reliable marker of disease progression. Participants must have a confirmed Parkinson's diagnosis and no major eye movement problems at the start.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2021
- Expected to finish
-
Jan 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
\*Inclusion Criteria: 1. Male or Female; 2. Clinically defined idiopathic Parkinson's Disease (PD); 3. Brain MRI performed in routine care in the 12 months preceding inclusion; 4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation; 5. Hoehn \& Yahr score: 1 to 3; 6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted); 7. Neuro-cognitive disorders: absent or minor (according to DSM5); 8. Sufficient written and oral expression in French; 9. Covered by a health insurance system; 10. Written informed consent signed by the patient; 11. Presence of a caregiver. \* Exclusion Criteria: 12. Psychiatric comorbidity (except anxiety or mild to moderate depression); 13. Neurological comorbidity, if significant; 14. Brain MRI showing: 1. significant cerebrovascular pathology (Fazekas I admitted), 2. another brain disease, including stroke. 15. Major cognitive impairment; 16. Absolute exclusion criteria and "Red flags" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system: * Cerebellar syndrome * Vertical oculomotricity disorders on clinical examination * Motor symptoms restricted to the lower limbs * Bilateral and perfectly symmetrical parkinsonism * Early dystonia * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD) * Progressive aphasia or apraxia * Moderate or severe postural instability and / or early falls * Early bulbar dysfunction (dysarthria, swallowing disorders) * Ventilatory dysfunction (inspiration) * Severe dysautonomia * DOPA-resistance * Neuroleptic treatment or related 17. Normal MIBG myocardial scintigraphy (if performed).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease, idiopathic are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital
RECRUITINGMonaco, 98000, Monaco
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a tailored supplement boost nutrition while preserving Parkinson's drug power?
- Brain Implant's hidden impact on voice and swallowing in Parkinson's
- Sound waves aim to ease Parkinson's tremors
- AI wearable could spot Parkinson's freezing episodes at home
- Smarter brain stimulation may give Parkinson's patients more good hours each day
- Could your phone detect Parkinson's? new study tests remote monitoring and skin tests